

February 25-27, 2025 | Boston, MA

www.as-immunetolerance.com



8th Annual

Antigen-Specific Immune Tolerance Summit

Advancing Curative Therapies for Autoimmune Diseases

Identify Antigens Driving Autoimmune Disease & Biomarkers of Tolerance, Explore Novel Delivery Systems, & Evaluate Clinical Trials for Efficacious & Durable Antigen-Specific Immune Tolerance Therapies

Expert Speakers Include:



Anton Lindqvist
Chief Scientific Officer
Diamyd Medical



Melissa Matzelle
Associate Director – Immunology Search & Evaluation
AbbVie



José Carballido
Executive Director – Translational Medicine & Preclinical Safety
Novartis



Aaron Winkler
Immune Tolerance Lead and Senior Scientific Director, Inflammation and Immunology
Pfizer



Kristie Grebe
Chief Scientific Officer
Anokion



Lauren Higdon
Director - Biomarker & Discovery Research
Immune Tolerance Network

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.as-immunetolerance.com [Antigen-Specific Immune Tolerance](#)



Welcome to the 8th Antigen-Specific Immune Tolerance Summit

Immune Tolerance Approaches Hold the Immense Power to Act as a Curative Solution for Autoimmune Diseases

Imagine a solution beyond standard immunosuppressive therapies, that can combat type 1 diabetes, celiac disease, multiple sclerosis, IBD and more...






This is the mission driving the **8th Antigen-Specific Immune Tolerance Summit**.

For 7 years, we have been at the forefront of groundbreaking research and development in immunology and inflammation and watched as the first immune tolerance therapies entered the clinic. In 2025, the 8th Antigen-Specific Immune Tolerance Summit will delve deeper into the complexities of immune tolerance as the tolerizing therapeutics landscape evolves with **Diamyd**, **Anokion**, **COUR** and more having their clinical trials underway and new approaches such as **mRNA-LNP** and **CAR-Treg** hitting the scene.

Join 120+ autoimmune, immunology and inflammation experts at this timely and comprehensive network to unite new and returning companies to build meaningful partnerships and gather insights beyond the literature to supercharge ASIT approaches to their full potential.

Don't miss out on this opportunity to explore antigens for tissue-specific tolerance, accelerate the translation of precision immunology therapeutics into the clinic and capitalize on the commercial and therapeutic opportunity that has the potential to truly transform the autoimmune field.

2025's meeting will delve into:

-  Delineating data on long-term efficacy, durability, and safety of antigen-specific therapies to further understand their viability as a therapeutic product
-  Delving into antigen-selection for complex autoimmune diseases with multiple antigens driving the disease to kickstart the expansion of ASIT therapies to larger patient populations
-  Evaluating the definition of tolerance and therefore biomarkers of tolerance that correlate with specific disease endpoints and biomarkers to inform clinical strategy and avoid bottlenecks in translational development
-  Optimizing drug development through the analysis of the latest clinical data to inform clinical strategy, improve efficacy and expedite the development of new therapies
-  Uncovering next generation mechanisms of actions and platform delivery technologies to select the most specific, targeted approach for inducing immune tolerance

KEY BENEFITS OF ATTENDING



Explore cutting-edge approaches in antigen selection for T and B-cells as a potential therapeutic to target complex, heterogenous autoimmune diseases with **Eli Lilly & Co.** and **AbbVie**



Highlight the progress of the antigen-specific immune tolerance space with the **latest phase 2 and phase 3 clinical data to inform clinical strategy** and progress precision medicines towards approval with **Diamyd Medical**, **Anokion** and **COUR Pharmaceuticals**



Delve into the **mechanisms and biomarkers used to assess immune tolerance** and establish standardized measures across disease indications with the **Immune Tolerance Network** and **PoITREG**



Evaluate the innovative use of **mRNA, cell therapy and nanoparticle technologies for enhanced tissue specificity** and durability of tolerizing therapeutics with **Genti Bio**, **Integrated Nanotherapeutics** and **Parvus Therapeutics**



Learn about the **key factors considered by large pharma companies** when evaluating potential partnerships and investments in immune tolerance therapies with insights from external innovation and partnership directors from **Eli Lilly & Co.**, **AbbVie**, **Genti Bio**

What's New for 2025?

9th Annual
Antigen-Specific
Immune Tolerance Summit

NEW

Antigen Discovery & Selection Seminar Day

Join the interactive, deep-dive, seminar day to get ahead of the curve in the novel technologies being developed in the world of antigen discovery.

Key Sessions:

- Panel: Current Approaches for Profiling the Autoimmune Response to Inform the Development of ASIT Therapies
- Understanding the Role of B-cells in Antigen Specific Immune Tolerance & their Potential as a Therapeutic Target
- Debating the Need for Disease Specific Autoantigens Vs Tissue Specific Antigens

Hear from **Pfizer, AbbVie, Eli Lilly & Co., The Karolinska Institute** and 4 other experts in this new addition, focused on early development.

New Clinical Readouts From:



New Preclinical Readouts From:



Large Pharma Collaboration Panel

Highly requested from the huge success over the last 2 years, the large pharma collaboration and external innovation panel is back and this year will include the perspectives of VCs and Biotech experiences

Hear from:



Brian Zhou
Associate Director –
Venture Science
Eli Lilly & Co.

Brian is part of the Lilly Venture team focusing on identifying early innovations to identify the next generation of medicine.



Melissa Matzelle
Director – Immunology
Search & Evaluation
AbbVie

Melissa supports the expansion of AbbVie's immunology portfolio through business development.



Martina Sassone-Corsi
Associate Director –
Discovery
GentiBio

Martina will share the experience of GentiBio on their partnered program with Bristol Myers Squibb.

Your 25+ Expert Speakers

9th Annual
Antigen-Specific
Immune Tolerance Summit



Aaron Winkler
Immune Tolerance Lead
and Senior Scientific
Director, Inflammation and
Immunology
Pfizer



Martina Sassone-Corsi
Associate Director –
Discovery
GentiBio



José Carballido
Executive Director –
Translational Medicine &
Preclinical Safety
Novartis



Brian Zhou
Associate Director –
Venture Science
Eli Lilly & Co.



Fiona McCann
Associate Director –
Pipeline Biology
Immunocore



Kristie Grebe
Chief Scientific Officer
Anokion



Weston Daniel
Chief Development Officer
EVOQ Therapeutics



Joanne Tan
Senior Vice President –
R&D
Parvus Therapeutics



Anton Lindqvist
Chief Scientific Officer
Diamyd Medical



Caroline Grönwall
Associate Professor
Karolinska Institutet



Melissa Matzelle
Director – Immunology
Search & Evaluation
AbbVie



Michael Birnbaum
Associate Professor –
Biological Engineering
**Massachusetts Institute
of Technology**



Heather Denroche, Ph.D.
Director, Preclinical
Development
**Integrated
Nanotherapeutics**



Lauren Higdon
Director - Biomarker &
Discovery Research
**Immune Tolerance
Network**



Charlotte Fribert
Chief Executive Officer
Toleranzia



Dan Shelly
Chief Business Officer
PoITREG



Natasha Girgis
Director – In vivo
Pharmacology
Cue Biopharma



Joe Podojil
Director - Immunology
COUR Pharmaceuticals



David Easterhoff
Director
Moderna



Ken Howard
Associate Professor
Aarhus University



Adam Elhofy
Vice President - Research
& Collaborations
COUR Pharmaceuticals



Geoffrey Lynn
Senior Vice
President - Synthetic
Immunotherapies
**Barinthus
Biotherapeutics**



Jessica Kenison
Director - Immunology
Immunocodex



Kevin White
Head of Immune Tolerance
AbbVie



Michael Engsig
Chief Executive Officer
Nykode Therapeutics



Joel Credle PhD
Director of Research &
Development, Scientific
Co-Founder
Infinity Bio

Antigen Discovery & Selection Seminar Day Tuesday, February 25



8.00 Registration & Coffee



Aaron Winkler
Immune Tolerance
Lead and Senior
Scientific Director,
Inflammation and
Immunology
Pfizer

8.50 Chair's Opening Remarks

Comprehensively Characterizing the Autoimmune Response to Ensure Relevant Antigens are Selected to Induce Antigen Specific Immune Tolerance

9.00 **Panel Discussion: Current Approaches for Profiling the Autoimmune Response to Inform the Development of ASIT Therapies**

- Inducing antigen-specific T-regulatory cells considering mRNA, peptide and nanoparticle approaches
- Inducing antigen specific B & T-cells
- Technologies available for antigen-specific autoimmune indications



Aaron Winkler
Immune Tolerance Lead and Senior Scientific
Director, Inflammation and Immunology
Pfizer



David Easterhoff
Director
Moderna



Caroline Grönwall
Associate Professor
Karolinska Institutet

9.30 **Understanding the Role of Antigen-Specific B-cells and Autoantibodies & Their Potential as Therapeutic Targets**

- Discussing the role of B cells in various autoimmune conditions and their potential as therapeutic targets
- Deciphering epitope specificity of pathogenic autoantibodies and autoreactive B cells
- Exploring the diversity of autoreactivity in patient subsets

10.00 **Round-table: Harnessing Antigen-Specific T-Cell Analysis to Successfully Characterize the Autoimmune Response**

This session provides the opportunity for smaller groups to come together, share learnings, analyze, debate, and discuss the below topics.

Identifying antigen
specific T-cell clones

Analyzing the diversity
of TCR responses

Isolating HLA peptides



10.30 Morning Refreshments & Networking

Selecting the Optimal Target in Antigen Specific Immune Tolerance Therapies – How Specific is Too Specific?



Jessica Kenison
Director - Immunology
Immunocodex

11.30 **Encoding Active Antigen-Specific Immune Tolerance Using mRNA-LNPs For the Treatment of Autoimmune Diseases**

- Discussion of the benefits gained by including an active immune modulator in antigen specific tolerance approaches
- Considerations when using an mRNA-LNP approach for autoimmunity
- Pre-clinical data in models of autoimmune disease.

Antigen Discovery & Selection Seminar Day Tuesday, February 25

8th Annual
Antigen-Specific
Immune Tolerance Summit

12.00 Panel: Debating the Need for Autoantigens Vs Tissue Specific Antigens

- Defining tolerance and the desired outcome, e.g. antigen-specific T-regs vs an immunosuppressive environment
- Discussing the number of antigens required for functional, disease-related tolerance
- Maintaining long-term tolerance through the regulation of epitopes
- Discussing the potential for redosing to maintain tolerance over time



Kevin White
Head of Immune Tolerance
AbbVie



David Easterhoff
Director
Moderna



Joe Podojil
Director - Immunology
COUR Pharmaceuticals



12.30 Lunch & Networking

Standardizing Platform Technologies to Enhance the Durability of ASIT Therapies

1.30 Roundtables – Turbocharging the Development of Standardized Platform Technologies

This session provides the opportunity for smaller groups to come together, share learnings, analyze, debate, and discuss the below topics.

Platform Technologies for
Identifying T-cell Epitopes

Humanized Animal Models for
Autoimmunity

Enhancing Sensitivity and
Specificity of TCR Immune Assays

2.00 Panel Discussion: Harnessing Technologies for Antigen Discovery & Selection

- Reviewing the landscape of technologies for antigen discovery and selection in development
- Approaches for antigen selection in diseases with well-defined antigens such as Type 1 Diabetes and Multiple Sclerosis
- Evaluating the potential for tackling complex, heterogenous diseases with antigen-specific immune tolerance approaches



Aaron Winkler
Immune Tolerance Lead and
Senior Scientific Director,
Inflammation and Immunology
Pfizer



Kevin White
Head of Immune Tolerance
AbbVie



Caroline Grönwall
Associate Professor
Karolinska Institutet

2.30 End of Preconference Day

“Excellent content. Excellent possibilities to discuss with peers.”
CEO, Amarna Therapeutics

“Excellent presentations. Lot of great speakers.”
IP & Business Analyst, COUR Pharmaceuticals

6

+1 617 455 4188 @ info@hansonwade.com

www.as-immunetolerance.com Antigen-Specific Immune Tolerance



Conference Day One

Wednesday, February 26



7.30 Registration & Coffee



José Carballido
Executive Director –
Translational Medicine
& Preclinical Safety
Novartis

8.20 Chair's Opening Remarks

Examining Clinical Trials for Efficacy & Safety in Immune Tolerance Approaches for Autoimmune Disease



Adam Elhofy
Vice President
– Research &
Collaborations
Cour Pharmaceuticals

8.30

NEW
DATA

Tolerogenic CNP-104 Treatment Regulates Th17 Cells Thereby Slowing PBC Progression and Liver Stiffness

- Demonstrating efficacy across multiple immunological and clinical mechanisms
- Highlighting the potential of CNP-105 to be the first disease-modifying treatment for PBC
- Delving into the safety and tolerability data supporting ASIT clinical studies



Anton Lindqvist
Chief Scientific Officer
Diamyd Medical

9.00

NEW
DATA

Updates on the Phase 3 Trial for an Antigen Specific Immune Tolerance Therapy for Type 1 Diabetes

- Discussing considerations for late-stage clinical trials for antigen specific approached to treating TD1
- Acknowledging regulatory requirements for precision medicine approaches for autoimmune diseases
- Navigating the use of a surrogate endpoint for BLA submission of precision medicine approaches



Joel Credle PhD
Director of Research &
Development, Scientific
Co-Founder
Infinity Bio

9.30

Mapping the Antibody Reactome at Scale with DNA-Barcoded Antigens

- Discussing the science of profiling antibody reactivities with DNA-barcoded antigen libraries
- Exploring the antibody reactomes in diseases for biomarker translational science
- Exploring the use of antibody reactivity profiling for mAbs development



Kristie Grebe
Chief Scientific Officer
Anokion

9.40

NEW
DATA

Clinical Evidence of Immune Tolerance Induction: Examples from Celiac Disease and Multiple Sclerosis

- Measuring immune tolerance through biomarkers in Celiac Disease
- Detection of antigen-specific tolerance to myelin-based autoantigens in MS; evaluation of bystander suppression and durability of responses
- Maximising patient safety in early clinical trials for inducing immune tolerance in the CNS



10.10 Speed Networking

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in the immune tolerance field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and technique applications.



10.40 Morning Refreshments

Conference Day One

Wednesday, February 26

Successfully Translating Antigen-Specific Tolerance Inducing Therapies for Clinical Success



Charlotte Fribert
Chief Executive Officer
Toleranzia

11.10 Proteins as Tolerogens to Induce Antigen Specific Immune Tolerance

NEW DATA

- Demonstrating TOL2's potential as a disease-modifying treatment for myasthenia gravis, supported by preclinical efficacy, safety, and biomarker data
- Discussing critical features of antigen-specific tolerogens to achieve clinical efficacy
- Considerations for first in human Phase I/IIa study of TOL2 in patients with generalized myasthenia gravis



Natasha Girgis
Director – Translational
Pharmacology
Cue Biopharma

11.40 Navigating the Use of Cytokines to Induce Antigen-Specific Immune Tolerance

- Exploring the use of IL-2 as a specific marker for CD4+ Treg production and its role in assessing ASIT induction
- Understanding the broader cytokine landscape and assessing the advantages and disadvantages of using cytokines such as IL-10, TGF- β , and IFN- γ as biomarkers of immune tolerance
- Addressing the impact of epitope spreading and bystander suppression to explore how these phenomena can influence biomarker interpretation and clinical outcomes



12.10 Lunch & Networking

Benchmarking Biomarkers of Immune Tolerance to Inform Reliable Clinical Endpoints



Lauren Higdon
Director - Marker &
Discovery Research
Immune Tolerance
Network

1.10

NEW DATA

Lessons Learnt from Type 1 Diabetes: Tolerance Mechanisms and Biomarkers

- Identifying biomarkers of response to immunotherapy
- Discussing optimal biomarkers to establish durability of immune tolerance
- Considering how biomarkers relate to mechanism of immune tolerance



Dan Shelly
Chief Business Officer
PoiTREG

1.40

Antigen-Specific Regulatory Cells and the Development of a T1D Vaccine: Clinically Derived Antigen-Specific Peptide-Based Modalities

- Review of clinical progress with Tregulatory cell therapies
- Development of a powerful Peptidomic and cell based assay platform for validating disease specific peptides from clinical samples
- Development of antigen-specific Tregulatory cell therapy and mRNA encoded peptide vaccine for Type 1 diabetes and other autoimmune diseases



2.10

Afternoon Refreshments & Poster Session

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversations and discussions. Explore a range of exciting poster presentations and showcase your own developments in the Antigen-Specific Immune Tolerance world. Don't miss out on the chance to submit your own posters and get ready to connect, learn, and present. To submit your poster please contact info@hansonwade.com

Conference Day One

Wednesday, February 26

Forging Strategic Alliances Across Biotech, Pharma & Investors to Advance Commercial & Scientific Breakthroughs in Immune Tolerance

2.40 Panel Discussion & Q&A - Collaborating with Large Pharma and VCs: What are They Looking for & What to Expect?

- Hear from large pharma, venture capitalists and experienced biotech leaders as they dive into the scientific and commercial factors of a setting up a successful partnership to develop ASIT therapies
- Uncover the key end-to-end key milestones that are evaluated when deciding on investment and partnership opportunities
- Ask your questions on what big pharma companies will be looking for next in their immunology and autoimmune portfolios



Melissa Matzelle
Associate Director – Immunology
Search & Evaluation
Abbvie



Brian Zhou
Associate Director – Immunology
Venture Science
Eli Lilly & Co.



Martina Sassone-Corsi
Associate Director – Discovery
Genti Bio



José Carballido
Executive Director –
Translational Medicine
& Preclinical Safety
Novartis

3.40 Chair's Closing Remarks

3.50 End of Conference Day 1

■■ Really great meeting! All the talks were high quality and sufficiently diverse to cover a lot of different angles. Everything ran smoothly and was effective for our team both to learn from others ■■

Scientist, Barinthus Therapeutics

■■ A diverse range of guests with energetic and enthusiastic chairs ■■

Scientific Project Manager, Armana Therapeutics

Conference Day Two

Thursday, February 27



7.30 Morning Registration & Coffee



José Carballido
Executive Director –
Translational Medicine
& Preclinical Safety
Novartis

8.20 Chair's Opening Remarks

Novel Technologies for Enhanced Tissue Specificity in Inducing Immune Tolerance



Heather Denroche, Ph.D.
Director, Preclinical
Development
**Integrated
Nanotherapeutics**

NEW
DATA

8.30 **Developing LNP/mRNA Therapeutics to Achieve Antigen-Specific Immune Tolerance**

- Highlighting the unique benefits of using a Multi-Cargo LNP approach to deliver autoantigens and modulate the immune system
- Discussing the biodistribution and mechanism of LNP/mRNA in inducing immune tolerance
- Showcasing the therapeutic potential of LNP/mRNA technology in type 1 diabetes and other autoimmune diseases



Martina Sassone-Corsi
Associate Director –
Discovery
Genti Bio

9.00 **Harnessing Antigen Specific CAR-Treg Cells for Enhanced Specificity Autoimmune Diseases**

- Engineering CAR-Treg cells that recognize self-antigen specific to the site of inflammation
- CAR-Tregs to enhance localization and the potency of Treg therapies to treat inflammatory bowel disease
- Discuss the potential advantages of antigen-specific CAR-Treg cells compared to Polyclonal Treg therapies



Geoffrey Lynn
Senior Vice
President - Synthetic
Immunotherapies
**Barinthus
Biotherapeutics**

9.30 **New insights into the MOA for systemic tolerance induction with IM administered SNAP-TI nanoparticles and updates on the clinical candidate VTP-1000**



10.00 Morning Refreshments & Networking

Nanoparticle Technologies for Enhanced Tissue Specificity in Inducing Immune Tolerance



Ken Howard
Associate Professor
Aarhus University

10.30 **Discussing a Biomolecular Assembly for “SupA-boosting” Immune Tolerance**

- Targeted cell delivery is required to induce immune tolerance
- Our SupA-Booster solution boosts immune tolerance by directing immune cell and lymph node trafficking



Joanne Tan
Senior Vice President –
R&D
Parvus Therapeutics

11.00 **Pioneering the Use of Nanoparticles to Enable Disease-Specific Immune Modulation**

- Uncovering the biologic and chemical components of targeted nanoparticles for disease specific effects
- Engineering nanoparticles to bind to specific autoantigen-experienced T-cells
- Outlining the advantages of tissue-specific targeting for a larger expansion of disease-specific Tregs



Joe Podojil
Director - Immunology
**COUR
Pharmaceuticals**

11.30 **Showcasing the Antigen-Specific CNP Nanoparticle Treatment Regulates CD8+ T Cells in a Model of Type 1 Diabetes**

- Developing nanoparticles that bind to monocytes and enhance uptake
- Ensuring optimal, targeted delivery of ASIT therapies through nanoparticles
- Harnessing COUR's nanoparticle technology to reprogram the immune system for a breakthrough approach to treating autoimmune disease

Conference Day Two

Thursday, February 27



Weston Daniel
Chief Development
Officer
EVOQ Therapeutics

12.00 Exploring the Nanodisc Platform for the Induction of Antigen-Specific Immune Tolerance

- Developing a proprietary technology that can effectively stimulate dendritic cells to orchestrate immune responses
- Manipulating dendritic cells to induce either immune activation or tolerance, depending on the stimulation they receive
- Efficiently delivers antigens to lymph nodes, where dendritic cells are concentrated, enhancing the immune response



12.30 Lunch & Networking

Demonstrating Tolerance Induction in Preclinical Models to Propel Immune Tolerance Therapies from Bench to Bedside



Michael Birnbaum
Associate Professor –
Biological Engineering
**Massachusetts
Institute of
Technology (MIT)**

1.30 Antigen-Specific Cell targeting for Antigen Discovery and Cell Reprogramming

- Understanding the targets of T and B cells is key to determining the mechanism of disease
- Targeting viral vectors via pMHC-TCR interactions can provide a means of decoding immunity as well as reprogramming cells for desirable function



Fiona McCann
Associate Director –
Pipeline Biology
Immunocore

2.00 Validating the Safety & Efficacy of Antigen Specific Immune Tolerance Therapies Using In Vitro & In Vivo Assays



- Evaluating the ability of APCs to present the target antigen to T-cells
- Discussing the advantages and disadvantages of animal models to study the autoimmune diseases
- Establishing correlation between in vitro and in vivo findings to identify consistent trends and patterns to validate efficacy



Michael Engsig
Chief Executive Officer
Nykode Therapeutics

2.30 APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance



- Latest updates on the development of Nykode's APC-targeted tolerogenic vaccines
- Novel pre-clinical PoC and MoA data in autoimmune disease models using different APC-targeting vaccine approaches

Future Directions: What's Next in Antigen Specific Immune Tolerance?

3.00 Panel Discussion: Practical Approaches for Creating a Compelling Preclinical Data Package for IND Submission to Move ASIT Therapies from the Lab to the Clinic

- Highlighting the importance of robust clinical data to secure funding, partnerships and regulatory buy-in in a new area with limited proof-of-concept studies
- Turbocharging the development of humanized mouse models and organoids to accurately replicate human autoimmune diseases for increased preclinical data
- Evaluating strategies for first in-human trials: when and where should the first patient be dosed?



Joanne Tan
Senior Vice President – R&D
Parvus Therapeutics



Kristie Grebe
Chief Scientific Officer
Anokion



José Carballido
Executive Director – Translational
Medicine & Preclinical Safety
Novartis



José Carballido
Executive Director –
Translational Medicine
& Preclinical Safety
Novartis

3.30 Chair's Closing Remarks

3.40 End of Conference

Partner With Us



Innovation Partner - Infinity Bio

Infinity Bio is a service company leveraging a proprietary antibody profiling platform that uses libraries of DNA-barcoded antigens (full human proteome, full human virome, allergome or custom), to provide detailed insights into an individual antibody reactivities. By comprehensively measuring the antibody reactome we can identify pre-existing or de-novo signatures of auto, anti-viral or anti-allergen antibody reactivities which could then reveal novel biomarkers of disease and clinical outcomes, or therapeutic targets.

Additionally, our platform can support mAbs deorphanization and cross-reactivity testing.



Miltenyi Biotec

Exhibition Partner - Miltenyi Biotec

Our mission is to advance scientific understanding and medicine by providing solutions for cell and gene therapy and biomedical research. We believe in biomedical science as the strongest driver to change the way we treat cancer, autoimmune diseases, and neurodegenerative disorders.

The design of therapeutics is evolving away from chemistry-based science towards individual treatments that focus on cell-based approaches and more targeted drugs. We are driving the revolution that is reinventing medicine and advancing it to a level that will make cancer and other serious diseases history.



Industry Partner - Barinthus Biotherapeutics

Barinthus Bio is an emerging leader in the research and development of antigen-specific immunotherapies that guide T cells to fight disease. We are building on a rich history of cutting-edge innovations by our scientific founders from leading institutions.

Barinthus Bio arose from the merger of Oxford University spinout Vaccitech, Plc and National Institutes of Health (NIH) and Johns Hopkins University spinout, Avidia Technologies, Inc. in 2021. Joining two leading immunotherapeutics companies with complementary technologies and expertise has created powerful synergies, fueling innovation and a focused pipeline of promising product candidates.

Very relevant and interesting talks
Scientist, Sail Biomedicines

GET INVOLVED



William Hobson-Corbett

Partnerships Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

Partner With Us



Industry Partner - Nykode Therapeutics

Nykode Therapeutics is an Oslo-based clinical-stage biopharmaceutical platform company founded in 2006. Our bold aim is to generate game-changing therapeutics to treat cancers and autoimmune diseases with a high unmet medical need.

With our unique and innovative modular vaccine technology, we're specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting immune responses.



Industry Partner - Aravax

Aravax uses proprietary technology to precisely reset the immune system to tolerate allergens without evoking allergic reactions during treatment. Aravax's lead product for peanut allergy (PVX108) is currently being tested in Phase 2 trials in adolescents and children in Australia and the United States. Aravax was founded in 2015 and closed a Series B funding round in January 2024. Aravax is backed by Brandon Capital Partners, Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper. The company's HQ is in Melbourne, Australia with additional operations in Oxford, UK.



Industry Partner - COUR Pharmaceuticals

COUR Pharma is a clinical-stage biotechnology company developing therapies to treat patients with autoimmune diseases. COUR's first-in-class therapies are based on our proprietary antigen-specific immune tolerance platform and are designed to reprogram the immune system to address the underlying root cause of immune-mediated diseases. Data from multiple clinical and preclinical programs have demonstrated the ability of COUR's product candidates to induce antigen-specific immune tolerance and have the potential to treat a wide range of autoimmune diseases including Primary Biliary Cholangitis, Type 1 Diabetes and Myasthenia Gravis.

<https://courpharma.com>

🗨️ Really great meeting! All the talks were high quality and sufficiently diverse to cover a lot of different angles. Everything ran smoothly and was effective for our team both to learn from others 🗨️

Scientist, Barinthus Therapeutics

GET INVOLVED



William Hobson-Corbett

Partnerships Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

